Beyond the Science: How European Biotechs Can Stand Out to Investors in 2026
ByDan Bennett
SHARE ON
Over the past few months, I have been travelling all across Europe, sitting down with biotech founders, CEOs, and key VC contacts in various life sciences hubs. What follows is an amalgamation of everything that I have learnt from these conversations.
While the therapeutic innovations I’ve seen are nothing short of incredible, a common theme dominated nearly every discussion: securing the next round of funding.
Whether you are targeting Venture Capital, Private Equity, or strategic pharmaceutical partnerships, the investment landscape in 2026 is unforgiving. Capital is available, but investors are highly risk-averse. Brilliant science is no longer enough to secure a term sheet; investors are looking for heavily de-risked, commercially viable assets.
If you are a European biotech gearing up for a funding round, here is a guide on how to make your organisation undeniable to investors right now.
Prove Commercial Viability (Not Just Clinical Efficacy)
The days of VCs funding a clinical trial and hoping for the best are over. Today, investors are funding commercial assets. If you have not mapped out your go-to-market strategy, you are already behind.
Market Access is King: A breakthrough therapy means nothing if payers won’t reimburse it. Investors want to see that you have a proactive Market Access strategy, particularly for stringent early-launch markets like Germany and the UK.
Target the 2030 Patent Cliff: Major pharma companies are staring down massive revenue losses by 2030 and are actively looking for assets to acquire. Frame your pipeline not just as a medical breakthrough, but as a strategic revenue-replacement asset for “Big Pharma.”
Build a “Been There, Done That” Leadership Team
Investors do not just invest in molecules; they invest in the people steering them. A common pitfall for early-stage biotechs is keeping a purely R&D-focused founding team in charge for too long.
The Regulatory & Clinical Heavyweights: Investors want to see that you have brought in seasoned leaders who have successfully navigated the EMA/FDA landscape before.
Early Commercial Hires: Hiring a fractional or full-time Commercial Director or Medical Affairs Lead 18 months before launch shows investors you are already paving the way with Key Opinion Leaders (KOLs) and setting the stage for revenue.
Integrate AI into Your DNA
As we’ve tracked in recent market data, AI is no longer a buzzword, it is a valuation multiplier. Biotechs that leverage technology to save time and capital are significantly more attractive to Private Equity and VCs.
Accelerated Timelines: Show investors how you are using AI to optimise clinical trial patient recruitment or accelerate drug discovery.
Predictive Value: Demonstrate how your team plans to use Real-World Evidence (RWE) and predictive analytics to build undeniable pricing models for European payers.
The Anatomy of a Winning Pitch Deck
Sophisticated life sciences investors review hundreds of decks a month. Keep yours under 20 slides, strip out the generic academic fluff, and focus on the commercial reality of your asset. Your deck must explicitly cover:
The Science & The Moat (Slides 1-3): Clearly articulate the Mechanism of Action (MoA) and your intellectual property strategy. How wide is your moat against biosimilars or competitors?
The Commercial Reality (Slides 8-10): Who is paying for this? Map out the target patient population, the competitive landscape, and your specific reimbursement strategy in Tier 1 European markets.
The “De-Risking” Team (Slides 11-13): Highlight the executives with commercial, regulatory, and exit experience. (This is where your talent strategy pays off).
Capital Efficiency & Inflection Points (Slides 14-16): Do not present a vague “runway.” Detail exactly how this specific funding round will propel the asset to the next value inflection point (e.g., clearing Phase IIb, securing Orphan Drug Designation).
The Exit Strategy (Slide 17): Name the likely acquirers. Which top 20 Pharma companies have pipelines that align with your asset as they face the 2030 patent cliff?
The Art of the Approach
Having a flawless deck and a brilliant asset is useless if you are pitching to the wrong room. Approaching investors requires surgical precision.
Do Your Homework: Align your outreach with the fund’s specific thesis. Do not pitch an early-stage oncology asset to a growth-equity fund focused on medtech. Know their ticket size, preferred clinical stage, and historical portfolio.
Warm Introductions are Crucial: Cold emails rarely secure term sheets in biotech. Leverage your Board of Directors, your existing Seed/Series A investors, and your strategic talent partners (who often have deep VC networks) to bridge the gap.
The “Pre-Pitch” Relationship: The best time to meet an investor is before you actually need their money. Introduce yourself at industry conferences (like Swiss Biotech Day or BIO-Europe), outline a milestone you plan to hit in the next 6 months, and then follow up when you successfully hit it. Execution builds trust.
The Key Takeaway for Founders
Talent and commercial foresight are the ultimate de-riskers. When you surround your brilliant science with a pitch that proves commercial viability, maps out an exit, and highlights a leadership team that knows how to execute, you shift your narrative from a “scientific gamble” to a “strategic investment.”
Are you a biotech leader currently navigating a funding round in Europe? What is the toughest feedback you are hearing from the market right now?
(And if you need to build out the kind of executive, medical, or commercial leadership team that makes investors take notice, or need an introduction to the right strategic partners, drop me an email. Let’s talk strategy).
